|
41
|
175
|
5dgjA |
1.0a resolution structure of norovirus 3cl protease in complex an oxadiazole-based, cell permeable macrocyclic (20-mer) inhibitor |
|
34
|
174
|
5dg6A |
2.35a resolution structure of norovirus 3cl protease in complex an oxadiazole-based, cell permeable macrocyclic (21-mer) inhibitor |
|
179
|
753
|
5d9aB |
Influenza c virus rna-dependent rna polymerase - space group p212121 |
|
179
|
753
|
5d98B |
Influenza c virus rna-dependent rna polymerase - space group p43212 |
|
100
|
378
|
4yptA |
X-ray structural of three tandemly linked domains of nsp3 from murine hepatitis virus at 2.60 angstroms resolution |
|
84
|
306
|
4yo9A |
Hku4 3clpro unbound structure |
|
207
|
563
|
5czbA |
Hcv ns5b in complex with ligand idx17119-5 |
|
112
|
321
|
5chsA |
N-terminal domain of the vesicular stomatitis virus l protein |
|
1
|
13
|
4xvjA |
Structure of the hepatitis c virus envelope glycoprotein e2 antigenic 2 region 412-423 bound to the broadly neutralizing antibody hc33.1 |
|
131
|
460
|
4y3cA |
I304v 3d polymerase mutant of emcv |
|
40
|
175
|
4xbdA |
1.45a resolution structure of norovirus 3cl protease complex with a covalently bound dipeptidyl inhibitor (1r,2s)-2-({n-[(benzyloxy)carbonyl]-3-cyclohexyl-l-alanyl}amino)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid (orthorhombic p form) |
|
309
|
878
|
4v0rA |
Dengue virus full length ns5 complexed with gtp and sah |
|
316
|
878
|
4v0qA |
Dengue virus full length ns5 complexed with sah |
|
141
|
466
|
4y2aA |
Crystal structure of coxsackie virus b3 3d polymerase in complex with gpc-n114 inhibitor |
|
40
|
183
|
4xbcA |
1.60 a resolution structure of norovirus 3cl protease complex with a covalently bound dipeptidyl inhibitor (1r,2s)-2-({n-[(benzyloxy)carbonyl]-3-cyclohexyl-l-alanyl}amino)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid (hexagonal form) |
|
152
|
460
|
4y2cA |
M300v 3d polymerase mutant of emcv |
|
39
|
175
|
4xbbA |
1.85a resolution structure of norovirus 3cl protease complex with a covalently bound dipeptidyl inhibitor diethyl [(1r,2s)-2-[(n-{[(3-chlorobenzyl)oxy]carbonyl}-3-cyclohexyl-l-alanyl)amino]-1-hydroxy-3-(2-oxo-2h-pyrrol-3-yl)propyl]phosphonate |
|
12
|
99
|
4x42A |
Crystal structure of den4 ed3 mutant with epitope two residues substituted from den3 ed3 |
|
31
|
138
|
4wznA |
Crystal structure of the 2b protein soluble domain from hepatitis a virus |
|
152
|
479
|
4wywA |
Mutant k20e of 3d polymerase from foot-and-mouth disease virus |
|
141
|
462
|
4wfxA |
Coxsackievirus b3 polymerase - f232l mutant - nacl crystal form |
|
151
|
445
|
4wxpA |
X-ray crystal structure of ns3 helicase from hcv with a bound fragment inhibitor at 2.08 a resolution |
|
153
|
478
|
4wylA |
Mutant k18e of 3d polymerase from foot-and-moth disease virus |
|
146
|
462
|
4wfzA |
Coxsackievirus b3 3dpol rna dependent rna polymerase - nacl crystal form |
|
81
|
306
|
4wy3A |
Structure of sars-3cl protease complex with a phenylbenzoyl (r,s)-n-decalin type inhibitor |
|
84
|
317
|
4wurA |
The crystal structure of the mers-cov papain-like protease (c111s) with human ubiquitin |
|
203
|
544
|
4wt9A |
Apo crystal structure of hcv ns5b genotype 2a jfh-1 isolate with e86q e87q s15g c223h v321i and delta8 mutations |
|
81
|
301
|
4x2zA |
Structural view and substrate specificity of papain-like protease from avian infectious bronchitis virus |
|
146
|
462
|
4wfyA |
Coxsackievirus b3 polymerase - f232l mutant - amso4 crystal form |
|
191
|
562
|
4txsA |
An ligand-observed mass spectrometry-based approach integrated into the fragment based lead discovery pipeline |
|
186
|
566
|
4ry4A |
C-terminal mutant (y448f) of hcv/j4 rna polymerase |
|
194
|
562
|
4tybA |
An ligand-observed mass spectrometry-based approach integrated into the fragment based lead discovery pipeline |
|
86
|
347
|
4s1tA |
Crystal structure of the mutant i26a/n52a of the endoribonuclease from human coronavirus 229e |
|
196
|
565
|
4ry7A |
C-terminal mutant (d559e) of hcv/j4 rna polymerase |
|
200
|
565
|
4ry5A |
C-terminal mutant (w550n) of hcv/j4 rna polymerase |
|
208
|
566
|
4tn2A |
Ns5b in complex with lactam-thiophene carboxylic acids |
|
76
|
347
|
4rs4A |
Crystal structure and mutational analysis of the endoribonuclease from human coronavirus 229e |
|
37
|
182
|
4u01A |
Hcv ns3/4a serine protease in complex with 6570 |
|
197
|
565
|
4ry6A |
C-terminal mutant (w550a) of hcv/j4 rna polymerase |
|
213
|
564
|
4tlrA |
Ns5b in complex with lactam-thiophene carboxylic acids |
|
85
|
306
|
4twyA |
Structure of sars-3cl protease complex with a phenylbenzoyl (s,r)-n-decalin type inhibitor |
|
194
|
562
|
4tyaA |
An ligand-observed mass spectrometry-based approach integrated into the fragment based lead discovery pipeline |
|
32
|
217
|
4qpiB |
Crystal structure of hepatitis a virus |
|
49
|
255
|
4rhv2 |
The use of molecular-replacement phases for the refinement of the human rhinovirus 14 structure |
|
48
|
246
|
4qpiC |
Crystal structure of hepatitis a virus |
|
40
|
236
|
4rhv3 |
The use of molecular-replacement phases for the refinement of the human rhinovirus 14 structure |
|
167
|
571
|
4r71B |
Structure of the qbeta holoenzyme complex in the p1211 crystal form |
|
48
|
273
|
4rhv1 |
The use of molecular-replacement phases for the refinement of the human rhinovirus 14 structure |
|
28
|
204
|
4qpgB |
Crystal structure of empty hepatitis a virus |
|
2
|
40
|
4rhv4 |
The use of molecular-replacement phases for the refinement of the human rhinovirus 14 structure |
